Page 59 - TD-3-4

Tumor Discovery PPAR agonist and cancer

doi: 10.1158/1535-7163.MCT-06-0763 crosstalk through nanocarrier systems. Stem Cell Rev
Rep. 2022;18(7):2209-2233.
109. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-β signaling
restores immune surveillance in the SMA-560 glioma doi: 10.1007/s12015-022-10426-9
model. Neuro Oncol. 2007;9(3):259-270.
119. Min JY, Kim DH. Stearoyl-CoA desaturase 1 as a therapeutic
doi: 10.1215/15228517-2007-010 biomarker: Focusing on cancer stem cells. Int J Mol Sci.
2023;24(10):8951.
110. Papi A, De Carolis S, Bertoni S, et al. PPARγ and RXR ligands
disrupt the inflammatory cross‐talk in the hypoxic breast doi: 10.3390/ijms24108951
cancer stem cells niche. J Cell Physiol. 2014;229(11):1595-1606.
120. Ma XL, Sun YF, Wang BL, et al. Sphere-forming culture enriches
doi: 10.1002/jcp.24601 liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as
111. Rovito D, Gionfriddo G, Barone I, et al. Ligand-activated a potential therapeutic target. BMC Cancer. 2019;19:1-2.
PPARγ downregulates CXCR4 gene expression through a doi: 10.1186/s12885-019-5963-z
novel identified PPAR response element and inhibits breast
cancer progression. Oncotarget. 2016;7(40):65109. 121. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic:
Glutamine metabolism to cancer therapy. Nat Rev Cancer.
doi: 10.18632/oncotarget.11371 2016;16(10):619-634.
112. Wang N, Wang S, Wang X, et al. Research trends in doi: 10.1038/nrc.2016.114
pharmacological modulation of tumor‐associated
macrophages. Clin Transl Med. 2021;11(1):e288. 122. Hay N. Reprogramming glucose metabolism in cancer:
Can it be exploited for cancer therapy? Nat Rev Cancer.
doi: 10.1002/ctm2.288 2016;16(10):635-649.
113. Penas F, Mirkin GA, Vera M, et al. Treatment in vitro with doi: 10.1038/nrc.2016.77
PPARα and PPARγ ligands drives M1-to-M2 polarization of
macrophages from T. cruzi-infected mice. Biochim Biophys 123. Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid
Acta. 2015;1852(5):893-904. metabolism in cancer metastasis. Mol Cancer. 2017;16(1):76.
doi: 10.1016/j.bbadis.2014.12.019 doi: 10.1186/s12943-017-0646-3
114. Souza-Moreira L, Soares VC, Dias SD, Bozza PT. Adipose- 124. Vamecq J, Colet JM, Vanden Eynde JJ, Briand G, Porchet N,
derived mesenchymal stromal cells modulate lipid Rocchi S. PPARs: interference with Warburg’ effect and
metabolism and lipid droplet biogenesis via AKT/mTOR– clinical anticancer trials. PPAR Res. 2012;2012(1):304760.
PPARγ signalling in macrophages. Sci Rep. 2019;9(1):20304. doi: 10.1155/2012/304760
doi: 10.1038/s41598-019-56835-8 125. Antonosante A, d’Angelo M, Castelli V, et al. The involvement
115. Gionfriddo G, Plastina P, Augimeri G, et al. Modulating of PPARs in the peculiar energetic metabolism of tumor
tumor-associated macrophage polarization by synthetic and cells. Int J Mol Sci. 2018;19(7):1907.
natural PPARγ ligands as a potential target in breast cancer. doi: 10.3390/ijms19071907
Cells. 2020;9(1):174.
126. Shi Q, Zeng Y, Xue C, Chu Q, Yuan X, Li L. Development
doi: 10.3390/cells9010174 of a promising PPAR signaling pathway-related prognostic
116. Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The prediction model for hepatocellular carcinoma. Sci
role of peroxisome proliferator-activated receptors (PPAR) Rep. 2024 Feb 28;14(1):4926.
in immune responses. Metabolism. 2021;114:154338. doi: 10.1038/s41598-024-55086-6
doi: 10.1016/j.metabol.2020.154338 127. Zhang Y, Li X, Zhang J, et al. Development and validation
117. Sun J, Yu L, Qu X, Huang T. The role of peroxisome proliferator- of the promising PPAR signaling pathway‐based prognostic
activated receptors in the tumor microenvironment, tumor prediction model in uterine cervical cancer. PPAR Res.
cell metabolism, and anticancer therapy. Front Pharmacol. 2023;2023(1):4962460.
2023;14:1184794. doi: 10.1155/2023/4962460
doi: 10.3389/fphar.2023.1184794
128. Wang H, Yang Y, Luo Q, et al. The PPAR signaling pathway
118. Nayak A, Warrier NM, Kumar P. Cancer stem cells and as a potential biomarker for the diagnosis of breast cancer.
the tumor microenvironment: Targeting the critical Int J Clin Exp Med. 2019;12(6):7327-7336.

Volume 3 Issue 4 (2024) 16 doi: 10.36922/td.4003